ATE429505T1 - Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung - Google Patents

Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung

Info

Publication number
ATE429505T1
ATE429505T1 AT97906764T AT97906764T ATE429505T1 AT E429505 T1 ATE429505 T1 AT E429505T1 AT 97906764 T AT97906764 T AT 97906764T AT 97906764 T AT97906764 T AT 97906764T AT E429505 T1 ATE429505 T1 AT E429505T1
Authority
AT
Austria
Prior art keywords
genetic
compositions
protective
therapeutic immunization
immunization
Prior art date
Application number
AT97906764T
Other languages
English (en)
Inventor
Franco Lisziewicz Juliana Lori
Original Assignee
Genetic Immunity Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Immunity Kft filed Critical Genetic Immunity Kft
Application granted granted Critical
Publication of ATE429505T1 publication Critical patent/ATE429505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97906764T 1996-02-21 1997-02-20 Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung ATE429505T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60462796A 1996-02-21 1996-02-21
PCT/US1997/002933 WO1997031119A1 (en) 1996-02-21 1997-02-20 Methods and compositions for protective and therapeutic genetic immunization

Publications (1)

Publication Number Publication Date
ATE429505T1 true ATE429505T1 (de) 2009-05-15

Family

ID=24420371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906764T ATE429505T1 (de) 1996-02-21 1997-02-20 Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung

Country Status (12)

Country Link
EP (1) EP0882134B8 (de)
JP (1) JP2000517290A (de)
AP (1) AP964A (de)
AT (1) ATE429505T1 (de)
AU (1) AU726623B2 (de)
CA (1) CA2246359A1 (de)
DE (1) DE69739372D1 (de)
EA (2) EA002020B1 (de)
ES (1) ES2324745T3 (de)
NZ (1) NZ331369A (de)
OA (1) OA10842A (de)
WO (1) WO1997031119A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3210997A (en) * 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
NZ503334A (en) * 1997-09-15 2002-05-31 Genetic Immunity Llc A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell
JP2002508338A (ja) * 1997-12-12 2002-03-19 ナルディニ，ルイジ レンチウィルスベクターの治療使用
WO1999047146A1 (en) * 1998-03-17 1999-09-23 Julianna Lisziwiewicz Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1372708B1 (de) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
EP1456230A2 (de) 2001-12-04 2004-09-15 Bavarian Nordic A/S Impfstoff aus der ns1-untereinheit eines flavivirus
EP1420822B2 (de) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
EP1590432A4 (de) * 2003-01-15 2008-05-14 Res Inst For Genetic And Human Dna-zusammensetzung und ihre verwendung
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
EP1797189A4 (de) * 2004-09-02 2010-05-19 Qun Chen Enkapsidationssystem zur herstellung rekombinanter virusähnlicher partikel
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
WO2009070639A1 (en) 2007-11-28 2009-06-04 Irx Therapeutics, Inc. Method of increasing immunological effect
WO2010009465A2 (en) * 2008-07-18 2010-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Htlv-ii vector and methods of use
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles

Also Published As

Publication number Publication date
NZ331369A (en) 2001-04-27
EP0882134B1 (de) 2009-04-22
EA002020B1 (ru) 2001-12-24
EP0882134A1 (de) 1998-12-09
AP964A (en) 2001-05-11
EA200100302A1 (ru) 2001-10-22
DE69739372D1 (de) 2009-06-04
AU726623B2 (en) 2000-11-16
OA10842A (en) 2001-08-14
AP9801320A0 (en) 1998-09-30
ES2324745T3 (es) 2009-08-13
CA2246359A1 (en) 1997-08-28
WO1997031119A1 (en) 1997-08-28
AU2136997A (en) 1997-09-10
EP0882134B8 (de) 2009-09-02
JP2000517290A (ja) 2000-12-26
EA199800746A1 (ru) 1999-02-25
EA003554B1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
DE69739372D1 (de) Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
DE69816789D1 (de) Verfahren und system zur gestengesteuerten optionsauswahl
ATE351910T1 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
DE69526825D1 (de) Verfahren und System zur Routenauswahl
DE69534416D1 (de) Verfahren und formulierungen zur bekämpfung von schadinsekten
DE69814155D1 (de) System und verfahren zur virtuellen eingabe
ATE397408T1 (de) Verfahren zur verbesserten bilderzeugung und photodynamischen therapie
DE69839261D1 (de) Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
DE69739887D1 (de) Verfahren und Einrichtung zur Blockverschlüsselung
DE69717922D1 (de) CD-ROM Wiedergabegerät und Verfahren zur Steuerung desselben
DE69622421D1 (de) Verfahren und zusammensetzungen zur verabreichung monomerer proteine
DE69429867D1 (de) Verfahren und einrichtung zur authentifizierung
DE69422718D1 (de) Gaserzeugende bitetrazoleaminzusammensetzungen und verfahren zur verwendung
DE69534867D1 (de) Verfahren und System zur Lieferung geschützter Gerätetreiber
DE59706789D1 (de) Sprachverarbeitungssystem und verfahren zur sprachverarbeitung
DE69635445T2 (de) Alkalialuminiumhydroxycarbonatzusammensetzung und verfahren zur herstellung
DE69831519D1 (de) System und Verfahren zur Lageermittlung
DE69721322D1 (de) Zusammensetzung und verfahren zur keimungshemmung bei kartoffeln
EP0871771A4 (de) Verfahren und zusammensetzungen zur durchführung der homologen rekombination
DE69717790D1 (de) Verfahren zur cdma codegenerierung und verfahren zur codeauswahl
DE69720131D1 (de) System und Verfahren zur Perspektivetransformation
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
DE69423129D1 (de) System und Verfahren zur Kurvendarstellung
DE69733137D1 (de) Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties